Sarcoidosis

Lancet

Volumn 361, Issue 9363, 2003, Pages 1111-1118

  Baughman, Robert P ^a,c   Lower, Elyse E ^a   Du Bois, Roland M ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; PENTOXIFYLLINE; PREDNISOLONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC REACTION; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; CYSTITIS; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; EYE TOXICITY; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; HYPERTENSION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INSOMNIA; LIVER TOXICITY; LUNG FIBROSIS; MAJOR HISTOCOMPATIBILITY COMPLEX; NAUSEA; NEUTROPENIA; OSTEOPOROSIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RISK FACTOR; SARCOIDOSIS; SOMNOLENCE; TREATMENT INDICATION;

EID: 0037471855     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12888-7     Document Type: Conference Paper

References (117)

1. Hills S.E., Parkes S.A., Baker S.B. Epidemiology of sarcoidosis in the Isle of Man-2: evidence for space-time clustering. Thorax. 42:1987;427-430.
2. Parkes S.A., Baker S.B., Bourdillon R.E., Murray C.R., Rakshit M. Epidemiology of sarcoidosis in the Isle of Man-1: a case controlled study. Thorax. 42:1987;420-426.
3. Hiraga Y. An epidemiological study of clustering of sarcoidosis cases. Nippon Rinsho. 52:1994;1438-1442.
4. Panayeas S., Theodorakopoulos P., Bouras A., Constantopoulos S. Seasonal occurrence of sarcoidosis in Greece. Lancet. 338:1991;510-511.
5. Bardinas F., Morera J., Fite E., Plasencia A. Seasonal clustering of sarcoidosis. Lancet. 2:1989;455-456.
6. Hosoda Y., Hiraga Y., Odaka M., et al. A cooperative study of sarcoidosis in Asia and Africa: analytic epidemiology. Ann N Y Acad Sci. 278:1976;355-367.
7. Edmondstone W.M. Sarcoidosis in nurses: is there an association? Thorax. 43:1988;342-343.
8. Hennessy T.W., Ballard D.J., DeRemee R.A., Chu C.P., Melton L.J. The influence of diagnostic access bias on the epidemiology of sarcoidosis: a population-based study in Rochester, Minnesota, 1935-1984. J Clin Epidemiol. 41:1988;565-570.
9. Sartwell P.E., Edwards L.B. Epidemiology of sarcoidosis in the US. Navy Am J Epidemiol. 99:1974;250-257.
10. Sarcoidosis among US Navy enlisted men, 1965-1993. MMWR Morb Mortal Wkly Rep 1997; 46:539-43.
11. Kern D.G., Neill M.A., Wrenn D.S., Varone J.C. Investigation of a unique time-space cluster of sarcoidosis in firefighters. Am Rev Respir Dis. 148:1993;974-980.
12. Prezant D.J., Dhala A., Goldstein A., et al. The incidence, prevalence, and severity of sarcoidosis in New York City firefighters. Chest. 116:1999;1183-1193.
13. Mitchell D.N., Rees R.J. A transmissible agent from sarcoid tissue. Lancet. 2:1969;81-84.
14. Hance A.J. The role of mycobacteria in the pathogenesis of sarcoidosis. Semin Respir Infect. 13:1998;197-205.
15. McGrath D.S., Goh N., Foley P.J., du Bois R.M. Sarcoidosis genes and microbes: soil or seed. Sarcoidosis Vasc Diffuse Lung Dis. 18:2001;149-164.
16. Vokurka M., Lecossier D., du-Bois R.M., et al. Absence of DNA from mycobacteria of the M. tuberculosis complex in sarcoidosis. Am J Respir Crit Care Med. 156:1997;1000-1003.
17. Ishige I., Usui Y., Takemura T., Eishi Y. Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis. Lancet. 354:1999;120-123.
18. Rybicki B.A., Kirkey K.L., Major M., et al. Familial risk ratio of sarcoidosis in African-American sibs and parents. Am J Epidemiol. 153:2001;188-193.
19. McGrath D.S., Daniil Z., Foley P., et al. Epidemiology of familial sarcoidosis in the UK. Thorax. 55:2000;751-754.
20. Rybicki B.A., Iannuzzi M.C., Frederick M.M., et al. Familial aggregation of sarcoidosis: a case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med. 164:2001;2085-2091.
21. Schürmann M., Lympany P.A., Reichel P., et al. Familial sarcoidosis is linked to the major histocompatibility complex region. Am J Respir Crit Care Med. 162:2000;861-864.
22. Ina Y., Takada K., Yamamoto M., et al. HLA and sarcoidosis in the Japanese. Chest. 95:1989;1257-1261.
23. Lenhart K., Kolek V., Bartova A. HLA antigens associated with sarcoidosis. Dis Markers. 8:1990;23-29.
24. Kunikane H., Abe S., Tsuneta Y., et al. Role of HLA-DR antigens in Japanese patients with sarcoidosis. Am Rev Respir Dis. 135:1987;688-691.
25. Grunewald J., Olerup O., Persson U., et al. T-cell receptor variable region gene usage by CD4+ and CD8+ T cells in bronchoalveolar lavage fluid and peripheral blood of sarcoidosis patients. Proc Natl Acad Sci USA. 91:1994;4965-4969.
26. Kunikane H., Abe S., Yamaguchi E., et al. Analysis of restriction fragment length polymorphism for the HLA-DR gene in Japanese patients with sarcoidosis. Thorax. 49:1994;573-576.
27. Nowack D., Goebel K.M. Genetic aspects of sarcoidosis. Class II histocompatibility antigens and a family study. Arch Intern Med. 147:1987;481-483.
28. Swider C., Schnittger L., Bogunia K.K., et al. TNF-alpha and HLA-DR genotyping as potential prognostic markers in pulmonary sarcoidosis. Eur Cytokine Netw. 10:1999;143-146.
29. Berlin M., Fogdell H.A., Olerup O., Eklund A., Grunewald J. HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. Am J Respir Crit Care Med. 156:1997;1601-1605.
30. Martinetti M., Tinelli C., Kolek V., et al. The sarcoidosis map. Am J Respir Crit Care Med. 152:1995;557-564.
31. Foley P.J., McGrath D.S., Petrek M., et al. HLA-DRB1 position 11 residues are a common protective marker for sarcoidosis. Am J Respir Cell Mol Biol. 25:2001;272-277.
32. Maliarik M.J., Chen K.M., Major M.L., et al. Analysis of HLA-DPB1 polymorphisms in African-Americans with sarcoidosis. Am J Respir Crit Care Med. 158:1998;111-114.
33. Silverman E.K., Palmer L.J. Case-control association studies for the genetics of complex respiratory diseases. Am J Respir Cell Mol Biol. 22:2000;645-648.
34. Grutters J.C., Sato H., Pantelidis P., et al. Increased frequency of the uncommon tumor necrosis factor 857T allele in British and Dutch patients with sarcoidosis. Am J Respir Crit Care Med. 165:2002;1119-1124.
35. Ishihara M., Ohno S., Ishida T., et al. Genetic polymorphisms of the TNFB and HSP70 genes located in the human major histocompatibility complex in sarcoidosis. Tissue Antigens. 46:1995;59-62.
36. Somoskovi A., Zissel G., Seitzer U., et al. Polymorphisms at position-308 in the promoter region of the TNF-alpha and in the first intron of the TNF-beta genes and spontaneous and lipopolysaccharide-induced TNF-alpha release in sarcoidosis. Cytokine. 11:1999;882-887.
37. Takashige N., Naruse T.K., Matsumori A., et al. Genetic polymorphisms at the tumour necrosis factor loci (TNFA and TNFB) in cardiac sarcoidosis. Tissue Antigens. 54:1999;191-193.
38. Yamaguchi E., Itoh A., Hizawa N., Kawakami Y. The gene polymorphism of tumour necrosis factor-beta, but not that of tumour necrosis factor-alpha, is associated with the prognosis of sarcoidosis. Chest. 119:2001;753-761.
39. Foley P.J., Lympany P.A., Puscinska E., Zielinski J., Welsh K.I., du B.R. Analysis of MHC encoded antigen-processing genes TAP1 and TAP2 polymorphisms in sarcoidosis. Am J Respir Crit Care Med. 160:1999;1009-1014.
40. Ishihara M., Naruse T., Ohno S., et al. Analysis of HLA-DM polymorphisms in sarcoidosis. Hum Immunol. 49:1996;144-146.
41. Ishihara M., Ohno S., Mizuki N., et al. Genetic polymorphisms of the major histocompatibility complex-encoded antigen-processing genes TAP and LMP in sarcoidosis. Hum Immunol. 45:1996;105-110.
42. Rybicki B.A., Maliarik M.J., Malvitz E., et al. The influence of T cell receptor and cytokine genes on sarcoidosis susceptibility in African Americans. Hum Immunol. 60:1999;867-874.
43. Furuya K., Yamaguchi E., Itoh A., et al. Deletion polymorphism in the angiotensin I converting enzyme (ACE) gene as a genetic risk factor for sarcoidosis. Thorax. 51:1996;777-780.
44. Maliarik M.J., Rybicki B.A., Malvitz E., et al. Angiotensin-converting enzyme gene polymorphism and risk of sarcoidosis. Am J Respir Crit Care Med. 158:1998;1566-1570.
45. McGrath D.S., Foley P.J., Petrek M., et al. ACE gene I/D polymorphism and sarcoidosis pulmonary disease severity. Am J Respir Crit Care Med. 164:2001;197-201.
46. Pietinalho A., Furuya K., Yamaguchi E., Kawakami Y., Selroos O. The angiotensin-converting enzyme DD gene is associated with poor prognosis in Finnish sarcoidosis patients. Eur Respir J. 13:1999;723-726.
47. Tomita H., Ina Y., Sugiura Y., et al. Polymorphism in the angiotensin-converting enzyme (ACE) gene and sarcoidosis. Am J Respir Crit Care Med. 156:1997;255-259.
48. Schürmann M., Reichel P., Muller-Myhsok B., et al. Angiotensin-converting enzyme (ACE) gene polymorphisms and familial occurrence of sarcoidosis. J Intern Med. 249:2001;77-83.
49. Mana J., Gomez V.C., Montero A., et al. Löfgren's syndrome revisited: a study of 186 patients. Am J Med. 107:1999;240-245.
50. Ward K., O'Connors C., Odlun C., Fitzgerald F.X. Prognostic value of bronchoalveolar lavage in sarcoidosis: the critical influence of disease presentation. Thorax. 44:1989;6-12.
51. Pinkston P., Bitterman P.B., Crystal R.G. Spontaneous release of interleukin-2 by lung lymphocytes in active pulmonary sarcoidosis. N Engl J Med. 308:1983;793-800.
52. Shigehara K., Shijubo N., Ohmichi M., et al. IL 12 and IL 18 are increased and stimulate IFN-gamma production in sarcoid lungs. J Immunol. 166:2001;642-649.
53. Baumer I., Zissel G., Schlaak M., Muller-Quernheim J. Th1/Th2 cell distribution in pulmonary sarcoidosis. Am J Respir Cell Mol Biol. 16:1997;171-177.
54. Ceuppens J.L., Lacquet L.M., Marien G., et al. Alveolar T-cell subsets in pulmonary sarcoidosis: correlation with disease activity and effect of steroid treatment. Am Rev Respir Dis. 129:1984;563-568.
55. Moller D.R., Forman J.D., Liu M.C., et al. Enhanced expression of IL 12 associated with Th 1 cytokine profiles in active pulmonary sarcoidosis. J Immunol. 156:1996;4952-4960.
56. Ziegenhagen M.W., Benner U.K., Zissel G., Zabel P., Schlaak M., Muller-Quernheim J. Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL 2R are prognostic markers. Am J Respir Crit Care Med. 156:1997;1586-1592.
57. Baughman R.P., Keeton D., Lower E.E. Relationship between interleukin-8 and neutrophils in the BAL fluid of sarcoidosis. Sarcoidosis. 11:1994;S217-S220.
58. Baughman R.P., Strohofer S.A., Buchsbaum J., Lower E.E. Release of tumour necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med. 115:1990;36-42.
59. Lynch J.P., Standiford T.J., Rolfe M.W., Kunkel S.L., Strieter R.M. Neutrophilic alveolitis in idiopathic pulmonary fibrosis. The role of interleukin-8. Am Rev Respir Dis. 145:1992;1433-1439.
60. Popper H.H. Epithelioid cell granulomatosis of the lung: new insights and concepts. Sarcoidosis Vasc Diffuse Lung Dis. 16:1999;32-46.
61. Hunninghake G.W., Costabel U., Ando M., et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis. 16:1999;149-173.
62. Daly P.A., O'Briain D.S., Robinson I., Guckian M., Prichard J.S. Hodgkin's disease with a granulomatous pulmonary presentation mimicking sarcoidosis. Thorax. 43:1988;407-409.
63. Lower E.E., Hawkins H.H., Baughman R.P. Breast disease in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 18:2001;301-305.
64. Warshauer D.M., Molina P.L., Hamman S.M., et al. Nodular sarcoidosis of the liver and spleen: analysis of 32 cases. Radiology. 195:1995;757-762.
65. Sulavik S.B., Spencer R.P., Palestro C.J., et al. Specificity and sensitivity of distinctive chest radiographic and/or 67Ga images in the noninvasive diagnosis of sarcoidosis. Chest. 103:1993;403-409.
66. Mana J., Teirstein A.S., Mendelson D.S., Padilla M.L., DePalo L.R. Excessive thoracic computed tomographic scanning in sarcoidosis. Thorax. 50:1995;1264-1266.
67. Remy J.M., Beuscart R., Sault M.C., Marquette C.H., Remy J. Subpleural micronodules in diffuse infiltrative lung diseases: evaluation with thin-section CT scans. Radiology. 177:1990;133-139.
68. Zajicek J.P., Scolding N.J., Foster O., et al. Central nervous system sarcoidosis - diagnosis and management. QJM. 92:1999;103-117.
69. Aoki J., Watanabe H., Shinozaki T., et al. FDG PET of primary benign and malignant bone tumours: standardized uptake value in 52 lesions. Radiology. 219:2001;774-777.
70. Lebtahi R., Crestani B., Belmatoug N., et al. Somatostatin receptor scintigraphy and gallium scintigraphy in patients with sarcoidosis. J Nucl Med. 42:2001;21-26.
71. Baughman R.P., Teirstein A.S., Judson M.A., et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 164:2001;1885-1889.
72. Pietinalho A., Ohmichi M., Hiraga Y., Lofroos A.B., Selroos O. The mode of presentation of sarcoidosis in Finland and Hokkaido, Japan. A comparative analysis of 571 Finnish and 686 Japanese patients. Sarcoidosis. 13:1996;159-166.
73. Honeybourne D. Ethnic differences in the clinical features of sarcoidosis in South-East London. Br J Dis Chest. 74:1980;63-69.
74. Rizzato G., Colombo P. Nephrolithiasis as a presenting feature of chronic sarcoidosis: a prospective study. Sarcoidosis. 13:1996;167-172.
75. Judson M.A., Baughman R.P., Teirstein A.S., Terrin M.L. Yeager H Jr, the ACCESS Research group. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. Sarcoidosis Vasc Diffuse Lung Dis. 16:1999;75-86.
76. Gibson G.J., Prescott R.J., Muers M.F., et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax. 51:1996;238-247.
77. Hunninghake G.W., Gilbert S., Pueringer R., et al. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med. 149:1994;893-898.
78. Rizzato G., Montemurro L., Colombo P. The late follow-up of chronic sarcoid patients previously treated with corticosteroids. Sarcoidosis. 15:1998;52-58.
79. Gottlieb J.E., Israel H.L., Steiner R.M., Triolo J., Patrick H. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest. 111:1997;623-631.
80. Neville E., Walker A.N., James D.G. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med. 208:1983;525-533.
81. Johns C.J., Michele T.M. The clinical management of sarcoidosis: a 50-year experience at the Johns Hopkins Hospital. Medicine. 78:1999;65-111.
82. Paramothayan S., Jones P.W. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA. 287:2002;1301-1307.
83. Israel H.L., Fouts D.W., Beggs R.A. A controlled trial of prednisone treatment of sarcoidosis. Am Rev Respir Dis. 107:1973;609-614.
84. Young R.L., Harkelroad L.E., Lorden R.E., Weg J.G. Pulmonary sarcoidosis: a prospective evaluation of glucocorticoid therapy. Ann Intern Med. 73:1970;207-212.
85. Pietinalho A., Tukiainen P., Haahtela T., Persson T., Selroos O. Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled, multicenter study. Chest. 116:1999;424-431.
86. Pietinalho A., Tukiainen P., Haahtela T., Persson T., Selroos O. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest. 121:2002;24-31.
87. du Bois R.M., Greenhalgh P.M., Southcott A.M., Johnson N.M., Harris T.A. Randomised trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study. Eur Respir J. 13:1999;1345-1350.
88. Baughman RP, Iannuzzi MC, Lower EE, et al. The use of fluticasone for acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis (in press).
89. Baltzan M., Mehta S., Kirkham T.H., Cosio M.G. Randomised trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med. 160:1999;192-197.
90. Jones S.K. Ocular toxicity and hydroxychloroquine: guidelines for screening. Br J Dermatol. 140:1999;03-07.
91. Sharma O.P. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurologic involvement. Arch Neurol. 55:1998;1248-1254.
92. Adams J.S., Diz M.M., Sharma O.P. Effective reduction in the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy. Ann Intern Med. 111:1989;437-438.
93. Baughman R.P., Lower E.E. Alternatives to corticosteroids in the treatment of sarcoidosis. Sarcoidosis. 14:1997;121-130.
94. Lower E.E., Baughman R.P. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med. 155:1995;846-851.
95. Muller-Quernheim J., Kienast K., Held M., Pfeifer S., Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J. 14:1999;1117-1122.
96. Lewis S.J., Ainslie G.M., Bateman E.D. Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 16:1999;87-92.
97. Baughman R.P., Lower E.E. A clinical approach to the use of methotrexate for sarcoidosis. Thorax. 54:1999;742-746.
98. Gedalia A., Molina J.F., Ellis G.S., et al. Low-dose methotrexate therapy for childhood sarcoidosis. J Pediatr. 130:1997;25-29.
99. Baughman R.P., Winget D.B., Lower E.E. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomised trial. Sarcoidosis. 17:2000;60-66.
100. Hunninghake G.W., Crystal R.G. Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. N Engl J Med. 305:1981;429-432.
101. Martinet Y., Pinkston P., Saltini C., et al. Evaluation of the in vitro and in vivo effects of cyclosporine on the lung T-lymphocyte alveolitis of active pulmonary sarcoidosis. Am Rev Respir Dis. 138:1996;1242-1248.
102. Wyser C.P., van Schalkwyk E.M., Alheit B., Bardin P.G., Joubert J.R. Treatment of progressive pulmonary sarcoidosis with cyclosporin A: a randomised controlled trial. Am J Respir Crit Care Med. 156:1997;1571-1576.
103. Bost T.W., Riches D.W., Schumacher B., et al. Alveolar macrophages from patients with beryllium disease and sarcoidosis express increased levels of mRNA for tumour necrosis factor-alpha and interleukin-6 but not interleukin-1 beta. Am J Respir Cell Mol Biol. 10:1994;506-513.
104. Pueringer R.J., Schwartz D.A., Dayton C.S., Gilbert S.R., Hunninghake G.W. The relationship between alveolar macrophage TNF, IL 1, and PGE2 release, alveolitis, and disease severity in sarcoidosis. Chest. 103:1993;832-838.
105. Baughman R.P., Lower E.E. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am Rev Respir Dis. 142:1990;1268-1271.
106. Marques L.J., Zheng L., Poulakis N., Guzman J., Costabel U. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med. 159:1999;508-511.
107. Zabel P., Entzian P., Dalhoff K., Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med. 155:1997;1665-1669.
108. Tavares J.L., Wangoo A., Dilworth P., et al. Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages. Respir Med. 91:1997;31-39.
109. Tramontana J.M., Utaipat U., Molloy A., et al. Thalidomide treatment reduces tumour necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med. 1:1995;384-397.
110. Carlesimo M., Giustini S., Rossi A., Bonaccorsi P., Calvieri S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol. 32:1995;866-869.
111. Baughman R.P., Judson M.A., Teirstein A.S., Moller D.R., Lower E.E. Thalidomide for chronic sarcoidosis. Chest. 122:2002;227-232.
112. Robinson B.W., McLemore T.L., Crystal R.G. Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. J Clin Invest. 75:1985;1488-1495.
113. Baughman R.P., Lower E.E. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 18:2001;70-74.
114. Yee A.M.F., Pochapin M.B. Treatment of complicated sarcoidosis with infliximab anti-tumour necrosis-alpha therapy. Ann Intern Med. 135:2001;27-31.
115. Kean J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumour necrosis factor-alpha neutralizing agent. N Engl J Med. 345:2001;1098-1104.
116. Baughman R.P., Bradley D.A., Raymond L.A., et al. Double blind randomised trial of a tumour necrosis factor receptor antagonist (etanercept) for treatment of chronic ocular sarcoidosis. Am J Respir Crit Care Med. 165:2002;A495.
117. Baughman R.P., Ohmichi M., Lower E.E. Combination therapy for sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 18:2001;133-137.